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1. Introduction
  
 The world faces a grave public health hazard in the 
aftermath of the third coronavirus pandemic, caused 
by a new coronavirus (severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), an infection 
with which can result in Covid-19 (Englisch et al. 
2021). COVID-19 patients often have severe symptoms 
such as acute respiratory distress syndrome (ARDS), 
inflammation, hypercoagulation, and thrombosis due 
to potential cytokine storm (Tan et al. 2021). The range 
of SARS-CoV-2 infections in a clinical context varies 
from asymptomatic to moderate upper respiratory 
tract disorders to severe respiratory pneumonia and 
even death (Zhou et al. 2020).
 After the interaction of viral Spike proteins S with 
ACE2 receptors, the COVID-19 virus penetrates in the 
lungs (Amini Pouya et al. 2020). The virus may thus 
produce histopathological lesions similar to those 
found in other types of ARDS (Merdji et al. 2021). 
Chest imaging, particularly computed tomography 
scan (CT-scan), is critical for diagnosing, treating, 
and following COVID-19 infected patients (Fang 
2020). The presence of ground-glass opacity (GGO) 
in COVID-19, for example, implies severe or chronic 
inflammation in the lungs and more severe symptoms 
such as bronchiolitis and pneumonia in both lungs 
and lung fibrosis (Sadhukhan et al. 2020). These areas 
of a lung infection can recruit various immune cells, 
leading to a pro-inflammatory reaction, including 
high IL-6 levels (Sadhukhan et al. 2020). These 
findings showed that lung abnormalities may lead to 
reduced oxygenation as a result of the chest CT scan 
(Sadhukhan et al. 2020).
 High mobility group box 1 (HMGB1) is a 
prototypical alarmin activating innate immunity and 
serves as a dual alarmin function (Andersson et al. 
2018). Extracellular HMGB1 triggers inflammation 
and recruits leukocytes to the site of tissue 
damage (Venereau et al. 2013) and is involved in 
inflammasome activation and autophagy (Tsung et 
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al. 2014). The DAMP family was identified by HMGB1 
as one of the earliest members. Inflammatory signals 
are generated by HMGB1 in several ways, by either 
direct activation of the toll-like receiver (TLR) 4 or 
by forming complexes with extracellular DNA, RNA, 
and other DAMP complexes (PAMPs) (Yang et al. 
2015). Several chronic inflammatory or autoimmune 
conditions are implicated in HMGB1 protein. For 
example, influenza-infected individuals who develop 
severe pneumonia have increased levels of HMGB1 in 
their bloodstream (Hou et al. 2014). Disease severity 
is associated with higher pro-inflammatory cytokines 
suggestive of a cytokine storm in the most severe 
COVID-19 patients (Zhou et al. 2020). HMGB1 levels 
were strongly associated with plasma IL-10 and IFN-, 
both of which are well-known indicators of COVID-19 
development (Chi et al. 2020). 
 Dickkopf-related protein 1 (DKK1) is a soluble 
protein that acts as an antagonist of the Wnt/β-
catenin signalling pathway (Mazon et al. 2018). By 
inhibiting Wnt/-catenin signalling and inducing 
cellular senescence, Dkk1 acts as a secreted growth 
inhibitor (Lyros et al. 2014). DKK1 was altered in many 
other illnesses with various methods that commonly 
end with the inflammatory pathway. The expression 
of serum DKK1 was elevated in individuals with 
lung cancer (Sun et al. 2020). Given that DKK1 is a 
well-known direct-catenin target gene, the reported 
stimulation of canonical Wnt/-catenin signalling 
might justify DKK1 overexpression (Lyros et al. 2019).
 SARS-CoV-2 uses the angiotensin-converting 
enzyme-2 (ACE2) as receptors when it enters the 
human body (Sinanović et al. 2020). Given the 
importance of the ACE2 receptor in the entrance of 
SARS-CoV-2 to enter host cells, the question of the 
involvement of ACE inhibitors and angiotensin-
receptor blockers (ARBs) in the pathogenesis of 
COVID-19 emerges as a highly complex relationship 
that is still highly contentious. On the one hand, it 
has been discovered in animal models that ACE 
inhibitors and ARBs can enhance the expression of 
ACE2 receptors (Wang et al. 2016), which presumably 
increases SARS-capacity CoV-2's to penetrate cells. 
However, the research on this is inconclusive, and it is 
possible that it is tissue-dependent, dose-dependent, 
and varies amongst ARBs (Wang et al. 2016).
 In the present study, an attempt was carried out 
to explore the role of some less-studied molecules 
in COVID-19 patients, namely, DKK1, HMGB1 on the 
level of COVID-19 receptor (ACE2). The effect of other 
parameters, including the lung abnormalities in the 
CT-scan and the saturation oxygen percentage (SpO2), 
on the levels of these parameters were examined.
2. Materials and Methods
2.1. Subjects
 The study has been authorized by the University 
of Kufa's Institutional Review Board (IRB) (177/2021). 
Before participating in this study, all controls and 
patients provided written informed permission. 
The study was done in compliance with Iraqi and 
international ethical and privacy regulations and the 
World Medical Association's Declaration of Helsinki.
 Sixty patients with confirmed SARS-CoV-2 
infection and thirty healthy controls were enrolled 
in this research. Between September and November 
2020, patients were recruited at the Al-Amal 
Specialized Hospital for Communicable Diseases, Al-
Hakeem General Hospital, Al-Shifa Health Center, and 
Al-Amal Specialized Hospital for Infectious Diseases 
in Najaf Governorate-Iraq between January 2020 till 
February 2021. SARS-CoV-2 infection was diagnosed 
based on positive reverse transcription real-time 
polymerase chain reaction (rRT-PCR) results for 
COVID-19 nucleic acids and positive IgM antibodies to 
SARS-CoV-2, as well as symptoms of acute infectious 
disease such as fever, fatigue, breathing difficulties, 
coughing, and loss of smell and taste. Patients with 
premorbid medical conditions such as diabetes, liver 
disease, chronic renal disease, neurodegenerative 
and neurologic diseases such as multiple sclerosis, 
Parkinson's, or Alzheimer's disease were excluded.
 We examined chest computed tomography 
(CT) images to detect lung abnormalities in CT-
scan (LACTS), which included GGOs, pulmonary 
densification regions consistent with residual 
lesions, pneumonic consolidation, and crazy-paving 
patterns (Kwee and Kwee 2020). We divided the 
patients into those who received (COVID+LACTS) and 
those who did not get (COVID-LACTS). The patients 
were then split into negative-IgG and positive-IgG 
subgroups based on their IgG findings to investigate 
the differences in the detected biomarkers between 
these subgroups. Additionally, 30 healthy controls 
were selected who were age and sex-matched to the 
patient groups. None of the controls had any systemic 
illness. However, as a public health measure to boost 
their resistance to COVID-19 infection, some healthy 
controls received zinc and vitamins C and D.
2.1.1. Measurements
 RT-PCR tests were performed on the patient during 
hospitalization using the Lyra® Direct SARS-CoV-2 Assay 
kits (Quidel Corporation, CA, USA) and the Applied 
Biosystems® QuantStudioTM 5 Real-Time PCR System 
(Thermo Fisher Scientific; Life Technologies Holdings Pte 
Ltd., Marsiling Industrial Estate, Singapore). The Lyra® 
Direct SARS-CoV-2 assay kit is a quantitative real-time 
reverse transcriptase-polymerase chain reaction (RT-
PCR) assay for detecting human coronavirus SARS-CoV-2 
from viral RNA isolated from nasal, nasopharyngeal, 
or oropharyngeal swab specimens.
 Fasting blood samples were collected in the early 
morning immediately following participation in the 
research. Five millilitres of venous blood were taken 
and placed in clean, simple tubes. After ten minutes, the 
clotted blood samples were centrifuged at 3,000 rpm 
for five minutes, and then the serum was separated and 
transferred to three fresh Eppendorf tubes until the assay. 
Samples that had been hemolyzed were discarded. The 
serum titer is calculated as the reciprocal of the highest 
dilution eliciting a positive reaction multiplied by the 
concentration of positive control. The following formula 
is used to estimate the CRP concentration in a patient 
sample: 6 times the CRP Titer equals mg/l. sACE2, DKK1, 
and HMGB1 levels in serum were determined using 
ELISA kits provided by Melsin Medical Co, Jilin, China. 
All kits utilized the sandwich method and demonstrated 
an inter-assay CV of less than 12%. Serum albumin, 
urea, creatinine, and glucose concentrations were 
determined spectrophotometrically using Biolabo® 
kits, Maizy, France. The processes were carried out 
exactly as specified by the manufacturer. To identify IgG 
and IgM in the serum of all participants, a qualitative 
ACON® COVID-19 IgG/IgM fast test was utilized. The 
kits have a 99.1 per cent sensitivity and a 98.2 per cent 
specificity.
2.1.2. Statistical Analysis
 The analysis of variance (ANOVA) was employed 
to analyze continuous variables, while the analysis of 
contingency tables (χ2-test) was utilized to evaluate 
nominal variables. Spearman's rank-order correlation 
coefficients determined the connections between 
biomarkers and clinical and cognitive scores. To identify 
connections between diagnoses and biomarkers, we 
used multivariate general linear models (GLMs). To 
compute the influence, partial eta-squared values 
were used. We used multiple regression analysis to 
find significant biomarkers while accounting for age, 
gender, and education effects. Statistical significance 
was found using a p-value of 0.05. All statistical analyses 
were done using IBM SPSS v25, 2017.
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3. Results
3.1. Demographic, Clinical, and Biochemical 
Biomarkers between COVID-19 Patients and 
Controls
The results of demographic and clinical data healthy 
controls (HC) and COVID-19 patients are presented 
in Table 1. There is no significant difference (p>0.05) 
between COVID-19 patients and the healthy control 
group in age, sex, BMI, and DBP, as shown in Table 1. 
Decreased SpO2 and albumin (p<0.05) were also seen in 
COVID-19 patients compared with the healthy groups. In 
patients, there is a substantial rise in body temperature 
(p<0.001) and SBP (p = 0.002). In COVID-19 patients, 
the percentages of the LACTS% are 40.67±11.84. There 
is a significant increase in the serum biochemical 
parameters (glucose, urea, creatinine, D-dimer, ACE2, 
DKK1, and HMGB1) in patients compared with the 
control group.  
3.2. Comparison between COVID-19 Patients 
with and without LACTS
The biomarkers in COVID-19 patients were divided 
into those with lung abnormalities, the chest CT scan 
(+LACTS) and without LACTS (-LACTS). The findings 
are presented in Table 2. The results showed that that 
+LACTS patients are slightly older (p<0.042) and have 
lower SpO2 (p = 0.019) than the -LACTS group. Patients 
with +LACTS also have a significant elevation in the 
serum levels of urea (p<0.001), creatinine (p = 0.008), 
glucose (p = 0.041), and HMGB1 (p<0.001). While other 
parameters showed no significant difference between 
-LACTS and +LACTS groups.
3.3. Correlation between ACE2, DKK1, and 
HMGB1 with Demographic and Clinical Data 
in COVID-19 Patients 
Table 3 shows the correlation between ACE2, DKK1, 
and HMGB1 with demographic and clinical data in 
COVID-19 patients. The correlation coefficients and the 
p-values for the correlation between ACE2, DKK1, and 
HMGB1 with the clinical and biochemical parameters 
in COVID-19 patients. ACE2 shows a significant 
correlation with SpO2 (ρ = 0.336, p<0.01) and a negative 
correlation with albumin (ρ = -0.197, p<0.05). DKK1 
have a significant correlation with HMGB1 (ρ = 0.316, 
p<0.01) and a negative correlation with albumin. Other 
parameters showed no significant correlation with the 
measured biomarkers.
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Table 1. Demographic and clinical data of healthy controls (HC) and COVID-19 patients
Table 2. Biomarkers in COVID-19 patients divided into those with lung abnormalities in the CT-scan (+LACTS) and without 
lung abnormalities (-LACTS)
Results expressed as mean±standard deviation for normally distributed data and binomial data were expressed as ratios. 
(*): analysis by Chi-squared test, ACE2: angiotensin-converting enzyme 2, BMI: body mass index, DBP: diastolic blood 
pressure, DKK1: Dickkopf-related protein-1, HMGB1: High-mobility group box 1 protein, IgG(M): immunoglobulin 
antibodies G (M), LACTS: lung abnormalities in CT-scan, SPO2: blood oxygen saturation and, SBP: systolic blood pressure
ACE2: angiotensin-converting enzyme 2, BMI: body mass index, DKK1: Dickkopf-related protein-1, HMGB1: High-mobility 
group box 1 protein, LACTS: lung abnormalities in CT-scan, and SPO2: blood oxygen saturation
Variables
Parameters
Lung abnormalities in CT-scan
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 The most important findings of the present study 
are the significant increase in the serum biochemical 
parameters (glucose, urea, creatinine, D-dimer, DKK1, 
and HMGB1) in patients compared with the control 
group, as seen in Table 1. Also, COVID-19 patients were 
having a severe state of hypoxia revealed from the low 
values of SpO2. In reality, most of the patients included in 
this study (82.7%) had hypoxemia, as measured by SpO2 
<92%. Furthermore, hypoxia can cause inflammation 
(Eltzschig et al. 2014) and increase ACE2 gene expression 
and protein levels in lung and renal tissues, all of which 
can contribute to the severity of COVID-19 (Shenoy 
et al. 2020). Peripheral oxygen saturation (SpO2) is 
frequently reduced in COVID-19, particularly in more 
severe instances and stages of LACT (Luks and Swenson 
2020).
 ACE2 is expressed in lung alveolar epithelial cells, 
small intestinal enterocytes, arterial and venous 
endothelial cells, and arterial smooth muscle cells 
(Hamming et al. 2004). According to the results of the 
study, ACE2 is not only a receptor for SARS-CoV-2, but it 
is also engaged in post-infection control, which includes 
immune response and adaptive immune responses, 
and cytokine production, and viral genome replication 
(Fischer et al. 2017). Additionally, it is hypothesized 
that higher soluble ACE2 function as a competitive 
interceptor of SARS-CoV-2, delaying viral entrance into 
cells and protecting against lung damage (Batlle et al. 
2020). SARS CoV2 induces ACE2 expression in various 
organs, including extensive beds of artery endothelial 
cells and even on the surfaces of many tissues other 
than the lung (Guan et al. 2020).
 DKK1 was shown to be substantially expressed in 
COVID-19 patients compared to controls in one study, 
particularly in severe cases, and it is expressed by 
epithelial cells (Le et al. 2021). DKK-1 changes might 
be used as indicators of inflammation in other illnesses. 
This is the most likely explanation for the change in 
DKK1 levels in COVID-19 patients. With improved 
glycemic control and low-dose aspirin treatment, 
plasma DKK-1 levels are reduced (Lattanzio et al. 
2014). ARDS is characterized by acute inflammation 
and increased coagulation cascade activity, increasing 
the risk of venous thromboembolic events (Paar et al. 
2021). The DKK1 receptor, which inhibits canonical 
Wnt signalling, also serves as an entrance receptor 
for many viruses (Staring et al. 2018).
 The level of HMGB1 was increased in COVID-19 
patients compared to healthy controls, as seen 
previously (Fan et al. 2021). In one research, HMGB1 
inhibition protected epithelial cells by stopping cytokine 
progress and also reduced viral replication (Gowda et 
al. 2021). In many human diseases, blood levels HMGB1 
are increasing, and HMGB1 is proposed as a good marker 
for severity of disease and prognosis (Ishida et al. 2011). 
Chronic inflammation may have consequences on 
Treg and Th17 cells due to HMGB1 and RAGE signal 
(Subramanian et al. 2017). Increased the levels of 
HMGB1 are secondary to necrosis/cell destruction in 
adipose tissue when the chronic inflammatory stage 
is high (Subramanian et al. 2017). Pathogenesis and 
specific symptoms of the illness can play a significant 
role in HMGB1/RAGE signalling and pro-inflammatory 
cytokines (Lui et al. 2016). Inflammatory neurons, 
microcytes and astrocytes are indicated for HMGB1 
to contribute to COVID-19 characteristics like fever, 
little taste loss and appetite through a Toll-like receptor 
4 (TLR4) (Andersson et al. 2020).
 The second finding is the presence of LACTS in more 
than half of COVID-19 patients and showed that about 
40% of lungs were having in the CT-scan indicating 
the lung injuries due to the SAR-CoV-2 infection. 
These abnormalities involved GGO, crazy-paving, 
consolidation in addition to other minor abnormalities 
as illustrated elsewhere (Adams et al. 2020). Some 
biomarkers levels have been changed in patients 
with positive lung abnormalities (+LACTS) than the 
patients without lung injuries (-LACTS). SARS-CoV‐2 
is more common than previously believed to cause 
lung involvement (Palmowski et al. 2020). 
 A report showed that SARS-CoV-2 might use ACE2 
tissue-protective mediator species-specific interferon-
driven overexpression after lung damage to increase 
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Table 3. Correlation between ACE2, DKK1, and HMGB1 
with demographic and clinical data in COVID-19 
patients
*: Correlation is significant (p<0.05)
**: Correlation is significant (p<0.01)
ACE2: angiotensin-converting enzyme 2, BMI: body mass 
index, DKK1: Dickkopf-related protein-1, HMGB1: High-
mobility group box 1 protein, LACTS: lung abnormalities 






























































infection (Ziegler et al. 2020). Lung damage leads to 
hypoxia, which may induce inflammation ACE2, and 
protein levels may be upregulated and may contribute 
to the degree of severity of COVID-19 in lung and renal 
tissues (Shenoy et al. 2020). Experimental investigations 
have shown that the medial use of HMGB1 by leucocytes 
in the lung is crucial in the mediation of acute lung 
damage (Huebener et al. 2019). Interestingly, HMGB1 
controls autophagy and may be an acute pulmonary 
damage biomarker (Qu et al. 2019). Autophagy is one 
of the mechanisms that involve viral entrance and cell 
replication, and thus a viable new treatment strategy 
for COVID-19 has been proposed for this process (Yang 
and Shen 2020). In addition, expression of HMGB1 is 
augmented in illnesses linked to thrombosis, and was 
investigated with alveolar epithelial cells (Pittet et al. 
2013). Severe inflammation has dual effects, and ACE2 
is raised since the lung abnormalities grow, leading to 
decreased oxygen supplies and the SpO2 ratio decreased 
(Al-Hakeim et al. 2021). The serum level of HMGB1 
was correlated with both the severity of pathogen-
associated tissue damage and excessive cytokine 
storm (Chan et al. 2012). In patients with COVID-19, 
the overproduced serum HMGB1 was related to unique 
cytokine storm characteristics(Entezari et al. 2014). 
Furthermore, HMGB1 serum was positive with a high CT 
score and oxygen demand at admission, which indicate 
the severity of acute lung damage and ARDS (Chen et 
al. 2020).
 The regular measurement of urea and creatinine 
is crucial in COVID-19 for acute renal injury (AKI). In 
the COVID-19 patients with independent risk factors 
for in-hospital death after the age, sex, severity of 
illness, comorbidities and the leukocyte count, elevated 
baseline blood creatinine and urea were raised (Cheng 
et al. 2020). The results indicated that the incidence of 
renal illness during inpatient hospitalization and in AKI 
development in patients with COVID-19 is significant 
and linked to inpatient death. The AKI treatment aim 
in COVID-19 is strongly justified (Cheng et al. 2020). 
A substantial percentage of the patients in hospital 
admission exhibited subclinical indications of renal 
dysfunctions that were not yet AKI, e.g. 59% proteinuria, 
44% hematuria, 14% higher blood urea nitrogen and 
10% higher serum creatinine, albeit slightly but poorer 
than those with other infections (Li et al. 2020). 
 The other important findings of the present study 
are the significant correlation between ACE2 with SpO2 
and the negative association with albumin. DKK1 have 
a significant correlation with HMGB1and a negative 
correlation with albumin. These correlations revealed 
the dependence of the level of these biomarkers with 
the hypoxia state and the increase of immunoglobulins 
fraction of plasma proteins that causes a reduction in 
the plasma albumin. Albumin and prealbumin level 
abnormalities are frequent in COVID-19 patients 
and may predict poor prognosis and should be 
carefully evaluated in clinical practice (Li et al. 2020). 
Hypoalbuminemia is prevalent in COVID-19 individuals 
and can be seen at an early stage of the illness. It is 
only linked to inflammatory indicators and clinical 
outcome (Bassoli et al. 2021). There has been minimal 
research on the relationship between blood albumin 
levels and COVID-19 disease severity (Kheir et al. 2021). 
In COVID-19 patients, hypoalbuminaemia may serve as 
a severity measure of epithelial-endothelial damage 
(Wu et al. 2021). Other results revealed that fibrinogen 
and D-dimer levels were more significant in the severe 
patients, whereas platelets count and albumin levels 
were significantly lower (Bi et al. 2020).
 In conclusion, COVID-19 patients are having 
an increase in the serum biochemical parameters 
(glucose, urea, creatinine, D-dimer, ACE2, DKK1, 
and HMGB1), in addition to a reduction in SpO2 
and albumin. COVID-19 patients had increased ACE, 
DKK1, and HMGB1, indicating that these biomarkers' 
pathways are involved in disease development. 
A large fraction of COVID-19 patients has had a 
sizeable LACTS percentage who were older and 
had lower SpO2 than those without LACTS. LACTS 
patients had significantly higher blood levels of 
urea, creatinine, glucose, and HMGB1. ACE2 has a 
significant relationship with SpO2 but a negative 
relationship with albumin. DKK1 has a significant 
relationship with HMGB1 and a negative relationship 
with albumin. The presence of LACTS and hypoxia 
in COVID-19 patients is linked to renal damage (as 
shown by elevated urea and creatinine levels) and 
serum HMGB1.
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